ISPOR - EE836 Cost-Effectiveness of Zolbetuximab Plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Adenocarcinoma in Taiwan

Full Text

EE836 Cost-Effectiveness of Zolbetuximab Plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Adenocarcinoma in Taiwan

Abstract

Authors

WM Huang NJ Chiang YW Tsai

Back to Volume 27, Supplemental Issue 12S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now